Anisodine Hydrobromide

Summary

Anisodine Hydrobromide (CHEMBL4779850) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including migraine with aura and migraine without aura.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 319.4 Da · C17H21NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4779850
Name	Anisodine Hydrobromide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	4105431
Molecular formula	C17H21NO5
Molecular weight	319.4
InChIKey	JEJREKXHLFEVHN-UHFFFAOYSA-N

SMILES: CN1C2CC(CC1C3C2O3)OC(=O)C(CO)(C4=CC=CC=C4)O

IUPAC name: (9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl) 2,3-dihydroxy-2-phenylpropanoate

Also known as: Anisodine hydrobromide, J3.145.635E, ANISODINE HYDROBROMIDE

Patent coverage: 287 distinct patent families (442 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
migraine with aura	3	MONDO:0005475	MONDO:0005475
migraine without aura	3	MONDO:0100431	MONDO:0100431

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05416476	PHASE3	UNKNOWN	Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
NCT07513233	PHASE1	RECRUITING	Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).